Genomic Instability in Ageing and Cancer
衰老和癌症中的基因组不稳定性
基本信息
- 批准号:7798341
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-10-01 至 2013-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeAging-Related ProcessAntioxidantsBiologicalBlood specimenCaringCell LineCell divisionCellsChemopreventionClinical ChemopreventionDNA biosynthesisDataDehydroascorbic AcidDemographic AgingDrug Delivery SystemsElderlyErythrocytesFarnesyl Transferase InhibitorFlow CytometryFrequenciesGenesGenomic InstabilityHumanIncidenceIndividualInterventionInvestigationLamin Type ALifeLinkLymphoid CellMalignant NeoplasmsMeasuresMembrane ProteinsMethodsMutationNeonatalNormal CellPatientsPharmaceutical PreparationsPhenotypePopulationPredispositionPremature aging syndromeProbabilityProcessProgeriaReactive Oxygen SpeciesRecruitment ActivityScreening procedureSentinelSomatic MutationSyndromeT-LymphocyteUmbilical Cord BloodUnited StatesVeteransX Chromosomeage groupage relatedbasecancer cellcancer riskcohortgranulocytehigh risklymphoblastoid cell linemutantolder patientpreventpublic health relevancetrendvolunteer
项目摘要
DESCRIPTION (provided by applicant):
Background: In humans, measuring the frequency (f) of cells harboring a mutation is possible for a very small number of sentinel genes and historically has been technically difficult. Measuring the mutation rate (<)--which represents the probability of new mutations occurring in a gene per cell division-- has been virtually impossible. Nevertheless, f and < may be key parameters in ageing. For example, it is hypothesized: (i) that < increases with age; (ii) that < is elevated in certain premature ageing syndromes; and (iii) that it might be possible to reduce ageing related cancers by decreasing <. We have now developed a robust method to measure these parameters using the PIG-A gene, which we hope will greatly facilitate the investigation of these hypotheses. PIG-A is on the X-chromosome- therefore a single inactivating mutation can produce the mutant phenotype. PIG-A mutants lack all GPI-linked membrane proteins, facilitating screening for rare cells with the GPI-null phenotype by flow cytometry. By this approach, we have been able to measure f in granulocytes, and both < and f in B lymphoblastoid cell lines and expanding cultures of ex vivo T lymphocytes from blood samples. Recently, we have shown that it is possible to measure f in human red cells in an additional sentinel gene, XK, which has similar advantages as PIG-A. Specific Aims (a): to determine whether < increases in humans as they age; (b): to determine whether it would be feasible to prevent ageing related cancers with pharmacologic agents that could decrease <. For aim (a), volunteer subjects in different age groups will be recruited, and < will be measured directly using PIG-A as a sentinel gene in B lymphoblastoid cell lines and T lymphocyte cultures, in comparison with neonatal cord blood samples. < will also be assessed indirectly, based on analysis of the frequency of granulocytes with PIG-A mutations and red cells with XK mutations as a function of age. For aim (b), using cells from normal older individuals and patients with progeria, the effect on the mutation rate will be determined for three pharmacologic approaches: quenching reactive oxygen species, modulating lamin A using farnesyltransferase inhibitors, and activating SIRT1. Preliminary data: < in cultures of lymphoid cells from normal individuals ranges from 3 to 53 x 10-7 mutations per cell division and is positively correlated with age. < is increased in cells from patients with cancer predisposition syndromes, premature ageing syndromes, and in malignant cell lines. A reduction in the spontaneous mutation rate in human cells has now been demonstrated using dehydroascorbic acid to reduce intracellular reactive oxygen species. Implications: Apart from addressing very important fundamental biological questions regarding ageing and cancer risk, studies under aim (a) are important for planning clinical chemoprevention studies. If < is constant throughout life, then any strategy to reduce mutations may need to start early. If however, as suspected, < starts to increase with age, it may be possible to prevent cancer by reducing < at a later age, once it starts to increase. Studies under aim (b) will be critical for predicting the optimal drug targets and pharmacologic strategy for reducing < clinically.
PUBLIC HEALTH RELEVANCE:
Narrative: The Department of Veterans' Affairs cares for a large cohort of elderly patients who are prone to cancer because they are elderly. A better understanding of the relationship between ageing and the mutation rate is very much needed to plan studies to prevent cancer in this population. The studies proposed here will help predict at what age intervention to decrease mutations might be required. These studies may also identify drugs that are likely to prevent mutations and cancer.
描述(由申请人提供):
背景资料:在人类中,测量携带突变的细胞的频率(f)对于非常少量的哨兵基因是可能的,并且历史上在技术上是困难的。测量突变率(<)-代表每次细胞分裂中基因发生新突变的概率-几乎是不可能的。然而,f和<可能是老化的关键参数。例如,假设:(i)<随着年龄的增长而增加;(ii)<在某些过早衰老综合征中升高;以及(iii)通过降低<可能减少与衰老相关的癌症。 我们现在已经开发出一种强大的方法来测量这些参数使用PIG-A基因,我们希望这将大大促进这些假设的调查。PIG-A位于X染色体上,因此单个失活突变可产生突变表型。PIG-A突变体缺乏所有GPI连接的膜蛋白,便于通过流式细胞术筛选具有GPI无效表型的罕见细胞。通过这种方法,我们已经能够测量粒细胞中的f,以及B类淋巴母细胞系和来自血液样品的离体T淋巴细胞的扩增培养物中的δ和f。 最近,我们已经表明,它是可能的测量f在人类红细胞中的一个额外的哨兵基因,XK,它具有类似的优势PIG-A。具体目标(a):以确定是否随着人类年龄的增长而增加;(B):以确定是否可以用可以减少的药理学试剂来预防与衰老相关的癌症。对于目的(a),将招募不同年龄组的志愿受试者,并将使用PIG-A作为B淋巴母细胞系和T淋巴细胞培养物中的哨兵基因直接测量,与新生儿脐带血样本进行比较。还将基于具有PIG-A突变的粒细胞和具有XK突变的红细胞的频率作为年龄的函数的分析来间接评估。对于目的(B),使用来自正常老年个体和患有早衰症的患者的细胞,将确定三种药理学方法对突变率的影响:淬灭活性氧物质、使用法尼基转移酶抑制剂调节核纤层蛋白A和激活SIRT 1。初步数据:在正常个体的淋巴细胞培养物中,每个细胞分裂的突变数为3至53 × 10-7,并且与年龄呈正相关。在来自患有癌症易感综合征、早衰综合征的患者的细胞中以及在恶性细胞系中, 现在已经证明使用脱氢抗坏血酸减少细胞内活性氧物质可以降低人类细胞中的自发突变率。 含义:除了解决有关衰老和癌症风险的非常重要的基本生物学问题外,目标(a)下的研究对规划临床化学预防研究也很重要。如果<在整个生命过程中是恒定的,那么任何减少突变的策略都需要尽早开始。然而,如果像怀疑的那样,<随着年龄的增长而开始增加,那么一旦<开始增加,就有可能通过在以后的年龄减少<来预防癌症。 目标(B)下的研究对于预测最佳药物靶点和减少临床<的药理学策略至关重要。
公共卫生相关性:
叙述:退伍军人事务部关心一大批老年患者,他们因为年老而容易患癌症。更好地了解衰老和突变率之间的关系是非常必要的,以计划研究,以预防这一人群的癌症。这里提出的研究将有助于预测在什么年龄可能需要干预以减少突变。这些研究还可能确定可能预防突变和癌症的药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David J. Araten其他文献
Pegcetacoplan Corrects Hyperbilirubinemia in Both Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and in Patients with PNH Who Previously Received Eculizumab
- DOI:
10.1182/blood-2022-166623 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
David J. Araten;Michael Yeh;Mohammed Al-Adhami;Regina Horneff;Federico Grossi - 通讯作者:
Federico Grossi
David J. Araten的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David J. Araten', 18)}}的其他基金
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
-- - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Directed Grant














{{item.name}}会员




